Impact of periprocedural major adverse events on 10-year mortality after revascularisation
Authors' conclusion
In patients with complex CAD, non-fatal PMAE were more common following CABG than PCI, but their prognostic impact was similar, being significant in the first year and then diminishing out to 10 years.
Study context
- Population
- Patients with three-vessel disease and/or left main disease enrolled in the SYNTAXES study
- Comparison
- Non-fatal periprocedural major adverse events (PMAE) vs no PMAE after percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
- Primary endpoint
- All-cause mortality by non-fatal PMAE within 30 days of PCI or CABG
- Follow-up
- 10 years
Primary result
As reported in the abstract
Non-fatal PMAE and all-cause mortality
- Non-fatal PMAE an independent predictor of all-cause mortality in the first year post-procedure, but not at 5 or 10 years, in both PCI and CABG
Further findings
Non-fatal PMAE incidence · within 30 days
P < 0.001
SSII-2020 10-year mortality predictions
- PMAE substantially alter individual predictions of 10-year mortality by SSII-2020
Optimal medical therapy (OMT) in patients with non-fatal PMAE
- OMT may provide survival benefits in the first year and long term
Original publication
Impact of periprocedural major adverse events on 10-year mortality after revascularisation. EuroIntervention. Published 20 March 2023. doi:10.
Summarised from the published abstract; every number is checked against it